# Study of ES414 in Metastatic Castration-Resistant Prostate Cancer

> **NCT02262910** · PHASE1 · COMPLETED · sponsor: **Aptevo Therapeutics** · enrollment: 35 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** ES414

## Key facts

- **NCT ID:** NCT02262910
- **Lead sponsor:** Aptevo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2018-12
- **Final completion:** 2019-02-18
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262910, "Study of ES414 in Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT02262910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*